![](https://cybin.com/wp-content/uploads/2023/01/Splotch-8-1.png)
Changing Minds®
A Breakthrough Neuropsychiatry Company
Latest Updates
![](https://cybin.com/wp-content/uploads/2024/03/FDA_PR_WebPage.png)
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
![](https://cybin.com/wp-content/uploads/2023/11/phase_2_003_PR_WebPage-4.png)
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
![](https://cybin.com/wp-content/uploads/2023/10/phase_2_003_dosing_PR_WebPage.png)
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
Missed Our
Breakthrough Therapy announcement on
March 13th, 2024?
![](https://cybin.com/wp-content/uploads/2024/04/Doug_Home_Page.webp)
![](https://cybin.com/wp-content/uploads/2024/04/Amir_Home_Page.webp)
![](https://cybin.com/wp-content/uploads/2023/01/Splotch-62@2x.png)
We’re on a mission to revolutionize mental healthcare.
At Cybin, we’re on a mission to revolutionize mental healthcare by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to address the unmet needs of patients across a multitude of mental health issues.
We are working with a network of world-renowned partners and pioneers in the field to create safe and effective psychedelic-based therapies. Together, we believe we can discover, develop and commercialize novel therapies that will transform the mental health treatment landscape.
![](https://cybin.com/wp-content/uploads/2022/05/j1-koy-MKNxcN6mkiY-unsplash-1-e1674406749403.jpg)
Led by Science
Our strategy is to combine novel psychedelic molecules with controllable drug delivery systems through our proprietary deuterated process. With our approach, we are engineering next-generation psychedelic, patent-protected, commercially scalable drug candidates to further evolve mental health treatments.
Novel Second-Generation Psychedelics based on well-known scaffolds including Psilocybin, DMT, MDMA with improved bioavailability.
Leveraging cutting-edge Neuroimaging technology to generate quantitative data to better understand psychedelic therapies.
Developing ground-breaking psychedelic facilitation training that supports leading clinical approaches to promote supportive healing with psychedelic medicine.
3 active drug programs targeting Major Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Generalized Anxiety Disorder (CYB004) and Neuroinflammation (CYB005).
250+ pre-clinical studies completed and progressing lead programs toward FDA IND filings.
>50 granted or pending patent applications filed across 6 patent families.
Backed by an
Experienced Team
Deep-rooted pharmaceutical and regulatory expertise across psychiatry and psychedelics drug development. Scientific leadership that includes work in addiction and psychedelics, oversight of 60+ IND programs with the FDA as well as success in developing multiple widely used commercially available prescription drugs.
![](https://cybin.com/wp-content/uploads/2022/05/Splotch-12-2-1.png)